HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV Exposure
Status:
Completed
Trial end date:
2019-09-17
Target enrollment:
Participant gender:
Summary
Principal objective Assess the operational efficacy of a strategy combining early diagnosis
and preventive antiretroviral treatment systematically reinforced from the birth* among
infants at high risk of infection with HIV** .
- in a maximum of 48 hours after delivery
- born from HIV infected mothers who received less than 4 weeks of antiretroviral
therapy prior delivery and / or HIV infection diagnosed at delivery
Intervention, a combined strategy :
After positive HIV infection screening from mother in the delivery room and put on
antiretroviral treatment of mothers with post partum according to national guidelines ,
newborns benefit :
- Early detection of HIV infection at birth
- Without awaiting the outcome of early detection result, a preventive reinforced
antiretroviral treatment (zidovudine, lamivudine, nevirapine or zidovudine, lamivudine
if their mother is infected with HIV-2), from birth for 12 weeks.
- Regular HIV screening until the end of breastfeeding or later to 18 months.
- In case of positive results of an HIV test, an antiretroviral treatment with zidovudine,
lamivudine, lopinavir, ritonavir whatever serology HIV 1 or 2.
Phase:
Phase 4
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)